Prostate Cancer Research Group publications
Selected highlight publications
1. Knowing what’s growing: Why ductal and intraductal prostate cancer matter, Science Translational Medicine, PMID: 32132214 Reprint.
2. Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer, Published on line 18th March, Clinical Epigenetics.
3. Taylor RA*, Fraser M*, Livingstone J*, Espiritu SMG*, Thorne H*, Huang V, Lo W, Shiah Y-J, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC**, Risbridger GP**, Bristow RG**. 2017. Germline BRCA2 Mutations Drive Prostate Cancers with Distinct Evolutionary Trajectories. Nature Communications 8: 13671.
4. Lawrence MG*, Obinata D*, Sandhu S*, Selth LA*, Wong SQ*, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, J Goad, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, kConFab, CASCADE, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA**, Risbridger GP** (2018) Patient-derived models of Abiraterone and enzalutamide resistant Prostate Cancer Reveal Sensitivity to ribosome directed therapy, European Urology EURURO 74 (2018) pp. 562-572; *Equal Authorship PMID 30049486.
5. Watt MJ, Clark AK, Whitby SJ, Haynes V, Wijayaratne PR, Matzaris M, Lo J, Huang C, Schittenhelm RB, Niranjan B, Rebello R, Furic L, Papargiris M, Norden S, Wu J, Febbraio M, Risbridger GP, Frydenberg M, Taylor RA (2019) Suppressing fatty acid uptake as a treatment for prostate cancer. Accepted, Science Translational Medicine. 6;11(478). PMID: 30728288.
6. GP Risbridger, RA Taylor, D Clouston, A Sliwinski, H Thorne, S Hunter, JLi, kConFab, GWE Mitchell, Murphy DGM, M Frydenberg, D Pook, J Pedersen, R Toivanen, H Wang, M Papargiris, MG Lawrence, DM Bolton. 2015. Patient derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. European Urology. 67(3):496-503.
7. Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan A, Pook D, Berman DM, Australian Prostate Cancer BioResource, Taylor RA, Risbridger GP. 2013. A pre-clinical model identifies castration-tolerant cancer repopulating cells in localized prostate tumors. Science Translational Medicine 5(187):187ra71.
8. Clark AK, Taubenberger AV, Taylor RA, Niranjan B, Chea ZY, Zotenko E, Sieh S, Pedersen J, Norden S, Frydenberg M, Grummet J, Pook DW, Australian Prostate Cancer BioResourse, Stirzaker C, Clark SJ, Lawrence MG, Ellem SJ, Hutmacher DW, Risbridger GP. 2013. A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials 34(20):4777-4785.
Additional publications
A full list of Prof Risbridger's publications can be viewed on PubMed.
A full list of A/Prof Taylor's publications can be viewed on PubMed.